Harel Insurance Investments & Financial Services Ltd. Buys 18,797 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Harel Insurance Investments & Financial Services Ltd. raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 52.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,425 shares of the company’s stock after purchasing an additional 18,797 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned approximately 0.05% of Neurocrine Biosciences worth $7,429,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of NBIX. State Street Corp raised its stake in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares during the period. Los Angeles Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after acquiring an additional 363,863 shares in the last quarter. Braidwell LP increased its holdings in shares of Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after acquiring an additional 158,665 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Neurocrine Biosciences by 45.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 472,929 shares of the company’s stock valued at $65,097,000 after purchasing an additional 147,907 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Neurocrine Biosciences by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock valued at $61,450,000 after purchasing an additional 102,715 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several research analyst reports. Barclays raised their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. BMO Capital Markets lowered their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. Finally, Wedbush reiterated an “outperform” rating and set a $148.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $164.81.

Neurocrine Biosciences Stock Up 0.8 %

NASDAQ:NBIX opened at $148.73 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 39.87 and a beta of 0.33. The stock’s 50 day moving average price is $134.09 and its two-hundred day moving average price is $131.46.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the sale, the chief executive officer now owns 135,392 shares of the company’s stock, valued at approximately $19,157,968. This represents a 32.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,694 shares of company stock valued at $9,676,730. 4.30% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.